FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4376271853> ?p ?o ?g. }

• W4376271853 endingPage "516" @default.
• W4376271853 startingPage "501" @default.
• W4376271853 abstract "Inflammatory bowel disease includes two chronic inflammatory diseases, ulcerative colitis and Crohn's disease. The burden of disease is increasing worldwide. A few reviews evaluating the pediatric use of tumor necrosis factor (TNF) antagonists have been published, although these mostly include observational studies and do not consider economic evaluations. This systematic review evaluated the available evidence regarding the efficacy, safety, and cost-effectiveness of TNF antagonist therapy for paediatric inflammatory bowel disease. We searched PubMed/MEDLINE, Embase, and Cochrane Central (up to May 2022). Nine randomized clinical trials and four economic evaluations that examined any anti-TNF drugs (e.g., infliximab, adalimumab, golimumab, certolizumab) against different alternatives were included. In studies evaluating the efficacy of anti-TNF drugs in Crohn's disease, most assessed the efficacy of maintenance regimen in patients who had previously responded to induction (response = 28%–63%, and clinical remission = 17%–83% depending on dose, drug, and follow-up). In ulcerative colitis, maintenance treatment with anti-TNF drugs reported clinical remission rates between 17%–44%. Nine studies reported information on adverse events. No clinical trials comparing different anti-TNF drugs were found. The findings from this review suggest that maintenance treatment with anti-TNF drugs (such as infliximab and adalimumab) in paediatric inflammatory bowel disease is probably effective and safe. However, the economic evaluations reported contradictory results of the cost-effectiveness ratios. Protocol registry: Open Science Framework: https://osf.io/wjmvf. La enfermedad inflamatoria intestinal incluye dos enfermedades crónicas inflamatorias, la colitis ulcerosa y la enfermedad de Crohn. Su carga de enfermedad está aumentando en el mundo. Se han publicado algunas revisiones que evalúan el uso pediátrico de los antagonistas del factor de necrosis tumoral (TNF), aunque incluyen mayoritariamente estudios observacionales y no consideran las evaluaciones económicas. En esta revisión sistemática se evalúa la evidencia disponible en cuanto a eficacia, seguridad y coste-efectividad de los antagonistas del TNF en el tratamiento de la enfermedad inflamatoria intestinal pediátrica. Se realizaron búsquedas en PubMed/MEDLINE, Embase y Cochrane Central (hasta mayo de 2022). Se incluyeron 9 ensayos clínicos aleatorizados y 4 evaluaciones económicas que estudiaran alguno de los fármacos anti-TNF (infliximab, adalimumab, golimumab, certolizumab) frente a diferentes alternativas. En los estudios que evaluaron la eficacia del tratamiento anti-TNF en enfermedad de Crohn, la mayoría valoraron la pauta de mantenimiento en pacientes que previamente habían respondido a la inducción (respuesta = 28%–63%, y remisión clínica = 17%–83% dependiendo de la dosis, fármaco y seguimiento). En colitis ulcerosa, el tratamiento de mantenimiento con anti-TNF presentó tasas de remisión clínica entre 17%–44%. Nueve estudios presentaron información sobre acontecimientos adversos. No se encontraron ensayos clínicos que compararan diferentes fármacos anti-TNF. Los resultados de esta revisión sugieren que el tratamiento de mantenimiento con fármacos anti-TNF (como infliximab y adalimumab) en la enfermedad inflamatoria intestinal pediátrica es probablemente eficaz y seguro. Sin embargo, las evaluaciones económicas incluidas presentaron resultados contradictorios sobre las razones coste-efectividad. Registro del protocolo: Open Science Framework: https://osf.io/wjmvf." @default.
• W4376271853 created "2023-05-13" @default.
• W4376271853 creator A5001192046 @default.
• W4376271853 creator A5045231943 @default.
• W4376271853 creator A5061121435 @default.
• W4376271853 date "2023-06-01" @default.
• W4376271853 modified "2023-09-29" @default.
• W4376271853 title "Tumour necrosis factor (TNF) antagonist therapy for paediatric inflammatory bowel disease: A systematic review" @default.
• W4376271853 cites W189377842 @default.
• W4376271853 cites W1915598702 @default.
• W4376271853 cites W1981017999 @default.
• W4376271853 cites W1984705525 @default.
• W4376271853 cites W1997836707 @default.
• W4376271853 cites W2000518155 @default.
• W4376271853 cites W2020640954 @default.
• W4376271853 cites W2043780895 @default.
• W4376271853 cites W2122667831 @default.
• W4376271853 cites W2133115874 @default.
• W4376271853 cites W2168550903 @default.
• W4376271853 cites W2171492921 @default.
• W4376271853 cites W2330344211 @default.
• W4376271853 cites W2405766149 @default.
• W4376271853 cites W2410892771 @default.
• W4376271853 cites W2560438049 @default.
• W4376271853 cites W2807688850 @default.
• W4376271853 cites W2946188292 @default.
• W4376271853 cites W2970684805 @default.
• W4376271853 cites W2981768636 @default.
• W4376271853 cites W2984471036 @default.
• W4376271853 cites W3011111308 @default.
• W4376271853 cites W3092023159 @default.
• W4376271853 cites W3105540265 @default.
• W4376271853 cites W3115409115 @default.
• W4376271853 cites W3144543375 @default.
• W4376271853 cites W3167734954 @default.
• W4376271853 cites W3175981068 @default.
• W4376271853 cites W4206405543 @default.
• W4376271853 cites W4211167126 @default.
• W4376271853 doi "https://doi.org/10.1016/j.medcle.2023.02.001" @default.
• W4376271853 hasPublicationYear "2023" @default.
• W4376271853 type Work @default.
• W4376271853 citedByCount "0" @default.
• W4376271853 crossrefType "journal-article" @default.
• W4376271853 hasAuthorship W4376271853A5001192046 @default.
• W4376271853 hasAuthorship W4376271853A5045231943 @default.
• W4376271853 hasAuthorship W4376271853A5061121435 @default.
• W4376271853 hasConcept C126322002 @default.
• W4376271853 hasConcept C168563851 @default.
• W4376271853 hasConcept C197934379 @default.
• W4376271853 hasConcept C2776478404 @default.
• W4376271853 hasConcept C2777138892 @default.
• W4376271853 hasConcept C2778260677 @default.
• W4376271853 hasConcept C2779134260 @default.
• W4376271853 hasConcept C2780132546 @default.
• W4376271853 hasConcept C2780479503 @default.
• W4376271853 hasConcept C2781290027 @default.
• W4376271853 hasConcept C2781413609 @default.
• W4376271853 hasConcept C71924100 @default.
• W4376271853 hasConcept C90924648 @default.
• W4376271853 hasConceptScore W4376271853C126322002 @default.
• W4376271853 hasConceptScore W4376271853C168563851 @default.
• W4376271853 hasConceptScore W4376271853C197934379 @default.
• W4376271853 hasConceptScore W4376271853C2776478404 @default.
• W4376271853 hasConceptScore W4376271853C2777138892 @default.
• W4376271853 hasConceptScore W4376271853C2778260677 @default.
• W4376271853 hasConceptScore W4376271853C2779134260 @default.
• W4376271853 hasConceptScore W4376271853C2780132546 @default.
• W4376271853 hasConceptScore W4376271853C2780479503 @default.
• W4376271853 hasConceptScore W4376271853C2781290027 @default.
• W4376271853 hasConceptScore W4376271853C2781413609 @default.
• W4376271853 hasConceptScore W4376271853C71924100 @default.
• W4376271853 hasConceptScore W4376271853C90924648 @default.
• W4376271853 hasIssue "11" @default.
• W4376271853 hasLocation W43762718531 @default.
• W4376271853 hasOpenAccess W4376271853 @default.
• W4376271853 hasPrimaryLocation W43762718531 @default.
• W4376271853 hasRelatedWork W1623606151 @default.
• W4376271853 hasRelatedWork W2042655884 @default.
• W4376271853 hasRelatedWork W2062990906 @default.
• W4376271853 hasRelatedWork W2080513478 @default.
• W4376271853 hasRelatedWork W2187503363 @default.
• W4376271853 hasRelatedWork W2327255580 @default.
• W4376271853 hasRelatedWork W2476663315 @default.
• W4376271853 hasRelatedWork W2611627410 @default.
• W4376271853 hasRelatedWork W2898455803 @default.
• W4376271853 hasRelatedWork W4226253339 @default.
• W4376271853 hasVolume "160" @default.
• W4376271853 isParatext "false" @default.
• W4376271853 isRetracted "false" @default.
• W4376271853 workType "article" @default.